Active	Status	Sponsor type	Region	Phase	Filter
2 Active 2 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Caras, Steven
NCT02560766: An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS	Recruiting	4	132	US	HORIZANT 300 mg, Gabapentin Enacarbil Extended-Release Tablets, HORIZANT 600 mg, Placebo	XenoPort, Inc.	RLS	10/23	10/23
NCT02633683: An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS	Recruiting	4	144	US	HORIZANT 600 mg, Gabapentin Enacarbil Extended-Release Tablets	XenoPort, Inc.	RLS	05/24	07/24